Neoleukin Therapeutics In... (NLTX)
NASDAQ: NLTX
· Real-Time Price · USD
3.49
0.05 (1.45%)
At close: Dec 18, 2023, 10:00 PM
Neoleukin Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 6.84M | 6.84M | n/a | n/a | n/a | n/a | n/a | n/a | 6K | 12K | 12K | 12K | 457K | 452K | 452K |
Cost of Revenue | 3.42M | 3.42M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 3.42M | 3.42M | n/a | -3.42M | -3.42M | -3.42M | -3.42M | n/a | 6K | 12K | 12K | 12K | 457K | 452K | 452K |
Operating Income | -127.07M | -106.72M | -50.95M | -43.9M | -38.05M | -46.09M | -58.89M | -59.13M | -60.01M | -61.85M | -61.11M | -60.69M | -29.39M | -11.69M | -6.31M |
Interest Income | 12.58M | 10.42M | 5.9M | 5M | 3.79M | 3.3M | 2.51M | 1.58M | 771K | 218K | 29K | 19K | 17K | 18K | 60K |
Pretax Income | -115.69M | -97.56M | -45.32M | -39.31M | -34.26M | -42.81M | -56.41M | -57.56M | -59.28M | -61.65M | -61.09M | -60.69M | -58.16M | -44.97M | -39.59M |
Net Income | -109.78M | -91.66M | -45.32M | -39.31M | -34.26M | -42.27M | -55.87M | -57.02M | -58.74M | -61.65M | -61.09M | -60.69M | -58.16M | -44.97M | -39.59M |
Selling & General & Admin | 29.51M | 26.3M | 19.65M | 17.79M | 16.72M | 15.91M | 17.33M | 17.97M | 19.13M | 20.55M | 20.93M | 21.51M | 20.95M | 19.25M | 18.88M |
Research & Development | 102.83M | 85.68M | 32.22M | 23.63M | 17.88M | 26.74M | 38.12M | 41.13M | 40.89M | 41.31M | 40.18M | 39.19M | 37.21M | 33.53M | 28.55M |
Other Expenses | 14K | 14K | n/a | -14K | -16K | -39K | -55K | -41K | -39K | -16K | -11K | -11K | -12K | -16K | -24K |
Operating Expenses | 132.34M | 111.99M | 51.87M | 41.41M | 34.6M | 42.64M | 55.45M | 59.1M | 60.02M | 61.86M | 61.12M | 60.7M | 58.16M | 52.79M | 47.43M |
Interest Expense | -21K | -19K | -7K | -4K | 816K | 1.38M | 1.57M | 1.58M | 771K | 218K | 29K | 19K | 17K | 18K | 60K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 66.6M | 72.17M | 8.63M | 20.35M | 34.6M | 42.64M | 55.45M | 59.1M | 60.02M | 61.86M | 61.12M | 60.7M | 58.16M | 52.79M | 47.43M |
Income Tax Expense | -5.91M | -5.91M | n/a | 5.91M | 5.1M | 4.56M | 4.18M | -1.71M | -911K | -380K | -3K | -19K | -17K | -18K | -60K |
Shares Outstanding (Basic) | 21M | 18.98M | 16.95M | 14.03M | 11.1M | 11.23M | 11.08M | 11.06M | 11.05M | 11.04M | 11.03M | 11.02M | 11.02M | 11.01M | 10.99M |
Shares Outstanding (Diluted) | 21M | 18.98M | 16.95M | 14.03M | 11.1M | 11.23M | 11.08M | 11.06M | 11.05M | 11.04M | 11.03M | 11.02M | 11.02M | 11.01M | 10.99M |
EPS (Basic) | -6.14 | -5.47 | -3.11 | -3.22 | -3.04 | -3.76 | -4.96 | -5.05 | -5.29 | -5.56 | -5.54 | -5.51 | -5.35 | -4.16 | -3.78 |
EPS (Diluted) | -6.14 | -5.47 | -3.12 | -3.23 | -3.05 | -3.77 | -4.96 | -5.05 | -5.29 | -5.56 | -5.54 | -5.51 | -5.35 | -4.16 | -3.78 |
EBITDA | -130.78M | -110.05M | -50.2M | -35.7M | -29.18M | -37.01M | -49.47M | -56.49M | -57.43M | -59.27M | -58.69M | -58.42M | -56.05M | -58.65M | -53.61M |
EBIT | n/a | -5.57M | -8.63M | -23.77M | -36.43M | -43.37M | -55.8M | -56M | -58.51M | -61.44M | -61.08M | -60.69M | -58.17M | -42.72M | -37.31M |
Depreciation & Amortization | -8.2M | -7.82M | 752K | 8.2M | 8.85M | 9.05M | 9.4M | 2.61M | 2.59M | 2.6M | 2.43M | 2.28M | 2.1M | 1.95M | 1.63M |